CPHL · Citi Pharma Ltd.
Financial Results for the Year Ended 30 June 2026
- Filed
- 5 October 2026 at 8:02 am
- Category
- Financials
- Sentiment
- Neutral
- Impact
- High
AI executive summary
Citi Pharma Limited reported its annual financial results for the year ended June 30, 2026, showing a consolidated net profit after tax of PKR 790.33 million compared to PKR 892.04 million in the prior year, alongside a basic earnings per share of PKR 3.46. Standalone profit after tax stood at PKR 782.60 million compared to PKR 892.04 million previously.
Key takeaways
- Consolidated sales net grew to PKR 14,075.80 million for the year ended June 30, 2026, up from PKR 13,153.52 million in the comparative period.
- Consolidated profit after tax declined to PKR 790.33 million (EPS: PKR 3.46) compared to PKR 892.04 million (EPS: PKR 3.90) in the prior year.
- Standalone profit after tax stood at PKR 782.60 million with an EPS of PKR 3.43 for the year ended June 30, 2026.
- Consolidated profit before taxation was recorded at PKR 1,344.51 million for the current period.
- Operating profit rose to PKR 1,940.39 million from PKR 1,604.25 million on a consolidated basis.
Filing details
Financial results
Annual · Audited · Consolidated · 30 June 2026
Figures in Rupees
Reporting period
Year
- Income
- 14,075,802,871 (prior 13,153,521,857)
- Profit after tax
- 790,333,542 (prior 892,038,934)
- EPS
- 3.46 (prior 3.9)
Dividend and entitlement
- Type
- None
- Entitlement date
- 21 October 2026
- Book closure
- 22 October 2026 – 28 October 2026
- Notes
- No cash dividend, bonus, or rights were recommended (NIL).
- #financial-results
- #annual-report
- #earnings
- #citi-pharma
This summary is AI-generated and may contain errors or omissions. Review the official PSX filing before making an investment decision.